• Explore /
  • Poster
  • / Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.

Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.

Abstract Poster

Authors

null

Rong Yin

Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China

Rong Yin , Siwei Wang , Ming Li , Feng Jiang , Jingyuan Zhang , Fanchen Meng , Wanxiangfu Tang , Hua Bao , Hanlin Chen , Xue Wu , Yang Shao , Jie Wang , Xianglin Zuo , Lin Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3038)

DOI

10.1200/JCO.2022.40.16_suppl.3038

Abstract #

3038

Poster Bd #

30

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Annual Meeting

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

First Author: Davina Gale

First Author: Damien Vasseur

First Author: Yinyin Chang

First Author: De-Zhen Guo